Neovasc Inc. is a medical device company specializing in the development of minimally invasive therapies for cardiovascular diseases, specifically targeting refractory angina and mitral valve regurgitation. The company operates in the global healthcare market, collaborating with researchers and clinicians in Canada, the United States, Europe, and the Middle East to ensure clinical rigor and innovation. Neovasc's primary products include the Reducer, which is CE marked for use in the EU and FDA approved for investigational use in the US, and the Tiara, which is currently undergoing clinical trials. The company's business model revolves around the research, development, and eventual commercialization of these medical devices. Revenue is generated through product sales, clinical trials, and potential future licensing agreements. Neovasc serves healthcare providers and patients suffering from complex cardiovascular conditions, aiming to improve patient outcomes through advanced medical technologies.

Keywords: cardiovascular, refractory angina, mitral valve regurgitation, medical devices, clinical trials, healthcare, minimally invasive, Reducer, Tiara, global collaboration.